gefitinib has been researched along with phenyl acetate in 2 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (phenyl acetate) | Trials (phenyl acetate) | Recent Studies (post-2010) (phenyl acetate) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 41,232 | 1,558 | 8,330 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, DR; Pawar, AA; Venkataraman, C | 1 |
| Kim, KS; Liu, W; Prakash, A; Zhang, C; Zhu, N | 1 |
2 other study(ies) available for gefitinib and phenyl acetate
| Article | Year |
|---|---|
Influence of precursor solvent properties on matrix crystallinity and drug release rates from nanoparticle aerosol lipid matrices.
Topics: Acetates; Aerosols; Antineoplastic Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chloroform; Crystallization; Crystallography, X-Ray; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Gefitinib; Hydrogen-Ion Concentration; Kinetics; Methylene Chloride; Microscopy, Electron, Transmission; Nanoparticles; Nanotechnology; Particle Size; Quinazolines; Solubility; Solvents; Stearic Acids; Technology, Pharmaceutical; Vapor Pressure | 2012 |
Targeting E. coli invasion of the blood-brain barrier for investigating the pathogenesis and therapeutic development of E. coli meningitis.
Topics: Acetates; Animals; Anti-Bacterial Agents; Blood-Brain Barrier; Brain; Ceftriaxone; Cells, Cultured; Cyclopropanes; Cysteine; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Escherichia coli; Female; Gefitinib; Humans; Infant, Newborn; Leukotriene Antagonists; Leukotrienes; Male; Meningitis, Escherichia coli; Mice; Permeability; Phospholipases A2, Cytosolic; Quinolines; Sphingosine-1-Phosphate Receptors; Sulfides | 2020 |